The presence of abundant tumor-infiltrating CD8+ T cells correlates with the expression of the PD-1 ligand PD-L1 in the same tumor areas and with increased clinical response rates to immune checkpoint blockers [7]. The gene discussed is CD8A; the disease is neoplasm.